Myriad Genetics, Inc (MYGN) concluded trading on Thursday at a closing price of $5.6, with 0.46 million shares of worth about $2.6 million changed hands on the day. Half year performance of the stock remained negative as price took a plunge of -58.91% during that period and on July 03, 2025 the price saw a loss of about -0.53%. Currently the company’s common shares owned by public are about 92.20M shares, out of which, 87.40M shares are available for trading.
Stock saw a price change of 5.07% in past 5 days and over the past one month there was a price change of 14.75%. Year-to-date (YTD), MYGN shares are showing a performance of -76.64% which decreased to -59.15% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $3.81 but also hit the highest price of $29.30 during that period. The average intraday trading volume for Myriad Genetics, Inc shares is 2.31 million. The stock is currently trading 8.32% above its 20-day simple moving average (SMA20), while that difference is up 6.82% for SMA50 and it goes to -56.67% lower than SMA200.
Myriad Genetics, Inc (NASDAQ: MYGN) currently have 92.20M outstanding shares and institutions hold larger chunk of about 102.47% of that.
The stock has a current market capitalization of $516.19M and its 3Y-monthly beta is at 1.91. It has posted earnings per share of -$1.12 in the same period. It has Quick Ratio of 1.71 while making debt-to-equity ratio of 0.22. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for MYGN, volatility over the week remained 5.39% while standing at 5.59% over the month.
Stock’s fiscal year EPS is expected to drop by -106.08% while it is estimated to increase by 1899.78% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Scotiabank on May 21, 2025 offering a Sector perform rating for the stock and assigned a target price of $6 to it. Stock get an Overweight rating from Piper Sandler on March 12, 2025.
